{"nctId":"NCT00105443","briefTitle":"A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma","startDateStruct":{"date":"2005-03"},"conditions":["Carcinoma, Hepatocellular"],"count":602,"armGroups":[{"label":"Sorafenib (Nexavar, BAY43-9006)","type":"EXPERIMENTAL","interventionNames":["Drug: Sorafenib (Nexavar, BAY43-9006)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Sorafenib (Nexavar, BAY43-9006)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Ages eligible for study: 18 years and above, Genders eligible for study: both\n* Patients who have a life expectancy of at least 12 weeks\n* Patients with histologically or cytologically documented Hepatocellular Carcinoma (HCC)\n* Patients must have at least one tumor lesion that meets both of the following criteria: (1) Accurately measured in at least one dimension according to RECIST (Response Evaluation Criteria in Solid Tumors) (2) Not previously treated with local therapy\n* Patients who have an ECOG (Eastern Cooperative Oncology Group) PS (Performance Status) of 0, 1, or 2\n\nExclusion Criteria:\n\n* Previous or concurrent cancer that is distinct in primary site or histology from HCC, EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta \\[Noninvasive papillary carcinoma\\], Tis \\[Carcinoma in situ: \"flat tumor\"\\] \\& T1 \\[Tumor invades subepithelial connective tissue\\]). Any cancer curatively treated \\> 3 years prior to entry is permitted\n* Renal failure requiring hemo- or peritoneal dialysis\n* History of cardiac disease\n* Active clinically serious infections\n* Known history of human immunodeficiency virus (HIV) infection\n* Known central nervous system tumors including metastatic brain disease\n* Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS)","description":"Overall Survival was defined as the time from date of starting treatment to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"324","spread":null},{"groupId":"OG001","value":"241","spread":null}]}]}]},{"type":"PRIMARY","title":"Time to Symptomatic Progression (TTSP)","description":"TTSP was defined as the time from randomization to the first documented symptomatic progression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null},{"groupId":"OG001","value":"148","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Progression (TTP)","description":"TTP was defined as the time from randomization to disease progression (radiological only). Subjects without tumor progression at the time of analysis were censored at their last date of tumor evaluation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"168","spread":null},{"groupId":"OG001","value":"86","spread":null}]}]}]},{"type":"SECONDARY","title":"Disease Control (DC)","description":"The DC is defined as the number of subjects with a best response rating of complete response (CR), partial response (PR), or stable disease (SD) that is maintained at least 28 days from the first manifestation of that rating. Definitions: CR = disappearance of all clinical and radiological tumor lesions; PR = at least 30% decrease in sum of the longest diameters of tumor lesions; SD = neither sufficient shrinkage to qualify for PR nor sufficient increase for progressive disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":null},{"groupId":"OG001","value":"96","spread":null}]}]}]},{"type":"SECONDARY","title":"Patients Reported Outcome (PRO) by Use of the FACT-Hep Questionnaire","description":"PRO is a disease-specific measure, developed as symptom-focused approach in HCC and measured by the response rates for the PWB and FWB subscales of the 45-item Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire. The FACT-Hep response rate was based on the number of subjects who achieved the 8-point minimally important difference (MID) for this subscale. FACT-Hep total score ranges from 0 to 180, where the highest score represents a maximum achievable quality of life (QoL) value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"151","spread":null},{"groupId":"OG001","value":"139","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]}]},{"type":"POST_HOC","title":"Overall Survival","description":"Overall Survival was defined as the time from date of starting treatment to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"327","spread":null},{"groupId":"OG001","value":"243","spread":null}]}]}]},{"type":"POST_HOC","title":"Time to Symptomatic Progression (TTSP)","description":"TTSP was defined as the time from randomization to the first documented symptomatic progression","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null},{"groupId":"OG001","value":"148","spread":null}]}]}]},{"type":"POST_HOC","title":"Time to Progression (TTP)","description":"TTP was defined as the time from randomization to disease progression (radiological only). Subjects without tumor progression at the time of analysis were censored at their last date of tumor evaluation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"168","spread":null},{"groupId":"OG001","value":"86","spread":null}]}]}]},{"type":"POST_HOC","title":"Disease Control (DC)","description":"The DC is defined as the number of subjects with a best response rating of CR, PR, or SD that is maintained at least 28 days from the first manifestation of that rating.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":null},{"groupId":"OG001","value":"96","spread":null}]}]}]},{"type":"POST_HOC","title":"Patients Reported Outcome (PRO) by Use of the FACT-Hep Questionnaire","description":"PRO is a disease-specific measure, developed as symptom-focused approach in HCC and measured by the response rates for the PWB and FWB subscales of the 45-item Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire. The FACT-Hep response rate was based on the number of subjects who achieved the 8-point minimally important difference (MID) for this subscale. FACT-Hep total score ranges from 0 to 180, where the highest score represents a maximum achievable quality of life (QoL) value. At the cut-off date for this analysis, one more patient data has been gained.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"151","spread":null},{"groupId":"OG001","value":"139","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":153,"n":297},"commonTop":["fatigue","diarrhea","pain, abdomen nos","anorexia","ascites"]}}}